Dermatological Drugs Market Forecast 2016-2026
Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma
What can be expected from the Dermatological Drugs Market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
Our 273-page report provides 208 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the all the major categories of the dermatological drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Dermatological Drugs submarkets:
• Skin Infections
See detailed profiles or revenue forecasts for some the leading products in the market
How will leading drugs perform to 2026? Our study provides detailed profiles or forecasts revenues for a number of drugs in the dermatological drugs market including:
See revenue forecasts for the leading international markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• EU5 – Germany, UK, France, Italy and Spain
Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Dermatological Drugs Market will reach $39.26bn in 2026. We predict a high revenue growth over the forecast period driven by an aging population, increasing patient expectations and a higher incidence of skin conditions, rapid growth of emerging economies and emerging dermatological drug technologies.
Our work analyses the key companies in the market. See Visiongain’s analysis of six leading companies, including these:
• Galderma (Nestle Skin Health)
• Johnson & Johnson
• LEO Pharma
A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the dermatological drugs industry?
Our new report discusses issues and events affecting the dermatological drugs market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future paradigm-shifting pipeline products
• Patent expirations and invalidations of major drugs
• Launches of new drug categories
• Biosimilar approvals
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma
In summary, our 273-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Dermatological Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading dermatological drugs in the following areas: psoriasis, skin infections, acne and dermatitis.
• Detailed profiles or revenue forecasts to 2026 for 25 of the leading products in the dermatological drugs market – discover prospects for leading dermatological drugs: Humira, Stelara, Enbrel, Remicade Taltz, Otezla, Cosentyx, Cubicin, Zyvox, Valtrex, Canesten, Lamisil, Bactroban, Solodyn, Epiduo, Claravis, Aczone, Differin, Abscorical/Epirus, Ziana, Doryx, Bepanthen/Bepanthol, Protopic, Dermovate and Elocon.
• Revenue forecasts to 2026 for eleven leading national market and one leading regional markets – US, EU5, China, Japan, India, Russia, and Braz.
• Assessment of six leading companies – analysis of products, revenue, mergers & acquisitions, product type and product pipelines
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the over the counter medicine market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6